Navigation Links
Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
Date:11/4/2008

es and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
2. Novavax CEO to Present at BIO Investor Forum 2008
3. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
4. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
5. Novavax Announces Closing of $18 Million Registered Direct Offering
6. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
7. Novavax to Join Russell 3000 Index
8. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
11. Novavax Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... USA (PRWEB) September 16, 2014 “Nature ... create the features that we desire in optical design,” ... at Montana State University. “As we explore surfaces and ... of those lessons were presented in San Diego in ... Light: Light in Nature ” chaired by Shaw and ...
(Date:9/16/2014)... --The emerging field of molecular electronics could take ... enabling the construction of tiny circuits from molecular ... would take on the roles currently played by ... of researchers from five Japanese and Taiwanese universities ... small-scale electronics: a molecule called picene. In a ...
(Date:9/16/2014)... Cardioxyl Pharmaceuticals, Inc. announced today ... to be effective in animal models following oral (capsule) ... infusions that could pave the way for convenient outpatient ... at the Heart Failure Society of America,s (HFSA) 18 ... Vegas . The research, conducted in ...
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... European Commission,s Joint Research Centre (JRC) has just ... a representative range of 25 different types of ... ensure consumer protection and confidence in many innovative ... most promising technological developments. By enabling a harmonised ...
... Feb. 14, 2011 New England Biolabs has expanded its ... One Taq Hot Start DNA Polymerases. Optimized blends of ... these new products offer robust amplification across a wide range ... exonuclease activity of Deep Vent increases the fidelity and robustness ...
... N.C., Feb. 14, 2011 India,s premier CRO, ... Society of India & Congress of Neurological Surgeons ...  The event was a convergence of leading neuroscientists, ... across the globe to discuss advances made in ...
Cached Biology Technology:Small material, big impact 2New England Biolabs Introduces OneTaq™ DNA Polymerase, a Robust Solution for Routine and Difficult PCR 2Max Neeman International Initiates Advisory Committee to Advance and Improve the Conduct of Complex Neurological Trials in India 2
(Date:9/16/2014)... Health at the Mailman School of Public Health are ... and prenatal exposure to two phthalates used in a ... the journal Environmental Health Perspectives . , ... levels of the chemicals, butylbenzyl phthalate (BBzP) and di-n-butyl ... increase in risk of developing asthma between age 5 ...
(Date:9/16/2014)... maternal morbidity amongst women in Australia is increased ... published today (17 September) in BJOG: An ... Australians generally enjoy high standards of living; however, ... in particular between indigenous and non indigenous Australians. ... independent impact of socioeconomic position on severe maternal ...
(Date:9/16/2014)... American Menopause Society (NAMS) has published its key, ... womenon everything from hot flashes to heart disease. ... Recommendations for Clinical Care of Midlife Women," was ... Menopause . This is the first, comprehensive set ... women freely available to all clinicians who care ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3
... Cambridge, Mass. - August 10, 2011 - Between conception ... meters long, looping and coiling within the tiny abdomen. ... loops into the same formationhowever, until now, it has ... experimental observations, biological and biophysical manipulations, theory, and computation, ...
... help overcome a major barrier to the use of gene ... reported development and successful initial laboratory tests of such a ... David Kaplan and colleagues note that gene therapy ... requires safe and efficient carriers or "vectors." Those carriers ...
... , Working out the structure of a complex formed ... be key in understanding how an antibiotic-producing organism controls ... example of how other antibiotic producers regulate export to ... certain microorganisms is a complex and highly regulated process, ...
Cached Biology News:Gut coils with help from its elastic neighbor 2Gut coils with help from its elastic neighbor 3Student brings home new expertise to answer question in antibiotic resistance 2Student brings home new expertise to answer question in antibiotic resistance 3
... Psychology, The University of New South Wales, Sydney, ... Perth, Australia This is the Fourth Edition of ... It is a large format version (330 ... compact 3rd edition. This product number includes ...
... Jouan RC10 series of vacuum concentrators/centrifugal evaporators ... features allied to rapid and safe concentration ... be combined with oil-free or high vacuum ... a wide selection of rotors (eliminating sample ...
... is Thermo Electron's most advanced personal gradient ... to use sophisticated onboard software and a ... to offer performance, accuracy and simplicity in ... of customer driven features built up on ...
Carrier Serum...
Biology Products: